Eye Journal

Naomi Tan and I are delighted to invite you to the Paediatric Ophthalmology Symposium at the @RCOphth Annual Congress 2026 in Manchester. Early bird registration is open until 24th March 2026: rcophth.ac.uk/events-courses… Please share! See you there 👀

[EYE OPEN] New review highlights key updates to the English Diabetic Eye Screening Programme: • 2-year screening for some low-risk patients • R2 retinopathy split into low/high risk • OCT used to refine maculopathy referrals Read #OpenAccess here: nature.com/articles/s4444…

Eye Reader’s Choice 2024–2025 Discover the most read and cited articles from Eye over the past two years. This collection brings together influential research, insightful reviews and expert commentary from across #ophthalmology. nature.com/collections/hi…

Pleased to share our paper published in @Eye_Journal: Feasibility and reproducibility of handheld and table-mounted optical coherence tomography in children with craniosynostosis nature.com/articles/s4143…

[Eye Open] Study finds macular disease patients are broadly accepting of AI in treatment decisions. Patients prioritise accuracy, speed, and the presence of a checking mechanism when considering the adoption of AI in treatment nature.com/articles/s4444… #Ophthalmology #OpenAccess

Members of The Royal College of Ophthalmologists can now publish colour figures in Eye at no additional cost. Benefit applies to the corresponding author and standard publication. Contact the Eye Editorial Office for full details. nature.com/eye/

New study shows a 23G trocar sleeve adapter can dramatically speed up silicone oil injection during vitreoretinal surgery. Injection time fell from 259s to 90s for Densiron 68, and from 774s to 153s for Silicone 5000 nature.com/articles/s4143… #Ophthalmology #OpenAccess

Changes in hyperreflective choroidal foci over time may predict treatment response and risk of pachychoroid macular atrophy in chronic central serous chorioretinopathy, supporting their role as prognostic biomarkers. Read now #OpenAccess: nature.com/articles/s4143… #Ophthalmology

Vigilance matters: in a 9-year UK study of 664 phthisical eyes, unsuspected intraocular malignancy occurred in 0.75% of cases, all after evisceration. Even with low risk, careful assessment and histopathology are essential. nature.com/articles/s4143… #Eyepathology #Ophthalmology

[Eye Open] New case report highlights a rare “pre-descemetocele” after DSAEK, showing that corneal melt can mimic a descemetocele even without Descemet’s membrane. Read the full article in Eye Open: nature.com/articles/s4444… #Ophthalmology #OpenAccess

The C-METRICAL system combines clinical assessment, OCT, angiography, and systemic factors to provide a unified framework, which could improve consistency in trials and everyday practice. Further studies are needed to test real world value.

[EYE OPEN] Diabetic macular oedema lacks a single, standard way to classify disease. That makes diagnosis, treatment decisions, and trial design harder. Could the C-METRICAL system be the solution? nature.com/articles/s4444… #Ophthalmology #OpenAccess

New UK clinical guidance published in @Eye_Journal aims to improve the identification and management of Charles Bonnet syndrome, a common but under-recognised consequence of sight loss. Read the full article: moorfieldsbrc.nihr.ac.uk/new-uk-clinica… @esmesumbrella | @Moorfields | @EyeCharity

📊 Investigating inherited retinal disorders in Scotland over 5 years! 🧬 RP & Stargardt are the most common diagnoses; 67% receive a molecular diagnosis, with ABCA4 & USH2A most common. 🔍 Benchmark for testing & future care. nature.com/articles/s4143… In @Eye_Journal

*NEW* EYE OPEN: Excimer-MLR, a rapid corneal neuroadaptive procedure, restored vision, improving visual acuity, contrast sensitivity, central fields and retinal sensitivity for up to two years in eyes with macular degeneration and holes. #Ophthalmology nature.com/articles/s4444…

Ocugen announced today the publication of Phase 1 GARDian1 trial data for #OCU410ST in @Eye_Journal. Results show favorable safety and tolerability with meaningful benefits in #Stargardtdisease after 12 months. Read more: bit.ly/4pzs0cE

🚨 NEW 🚨 Phase 1 data point to a promising advance for Stargardt disease type 1. In the GARDian1 trial, a single dose of OCU410ST was well tolerated, slowed retinal atrophy by about 50 percent, and improved vision over 12 months. @Ocugen #Ophthalmology nature.com/articles/s4143…

Are medical instructions designed for the patient's convenience, or the doctor's? With 1 in 6 UK adults facing literacy gaps, we overhauled our surgical post-op guides: fewer words, more visuals & video. Better access = better outcomes. nature.com/articles/s4143… #Ophthalmology

New real-world data over three years shows Hydrus Microstent and iStent inject W deliver comparable outcomes when combined with #cataract surgery for open angle #glaucoma, with similar IOP reduction, drop reduction and safety. nature.com/articles/s4143… #Ophthalmology

SPOTTED: One of Santa’s reindeer observed transiting the macula seen in an en face OCT retinal image 🦌 Many thanks to the team at the Southampton Eye Unit for this festive cover image. 🎄 nature.com/eye/volumes/39… #Ophthalmology